Combined bacterial populations under daptomycin + aztreonam therapy

The term "Combined bacterial populations under daptomycin + aztreonam therapy" does not refer to a single molecular target or receptor, but rather to a biological system or clinical treatment context involving pathogenic bacteria subjected to synergistic antibiotic pressure. This combination is primarily investigated for its efficacy against multidrug-resistant Gram-positive organisms, such as Methicillin-resistant Staphylococcus aureus (MRSA) and Vancomycin-resistant Enterococci (VRE). Daptomycin is a lipopeptide that disrupts bacterial membrane integrity, while aztreonam is a monobactam that inhibits cell wall synthesis (PubMed: 29133568). The synergy between these two agents is often attributed to the "seesaw effect," where the presence of a beta-lactam like aztreonam renders the bacterial membrane more susceptible to daptomycin by altering cell wall thickness or surface charge (PubMed: 24449771). This therapeutic strategy is typically reserved for refractory infections, such as persistent bacteremia or endocarditis, where standard monotherapies have failed to clear the pathogen.

Other names

Daptomycin-aztreonam combination therapyDAP-ATM synergyDaptomycin and aztreonam dual therapyBacterial populations under lipopeptide and monobactam pressure

Daptomycin acts by binding to the bacterial cytoplasmic membrane in a calcium-dependent manner, leading to membrane depolarization, ion leakage, and rapid cell death (StatPearls: NBK470467). Aztreonam is a monobactam that inhibits bacterial cell wall synthesis by binding to penicillin-binding protein 3 (PBP3) (StatPearls: NBK538234). In combination, aztreonam can induce structural changes in the cell wall (such as thinning) and alter the net surface charge of the bacteria, which enhances the binding and penetration of daptomycin, particularly in resistant strains like MRSA (PubMed: 24449771).